Abstract
The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Recent Patents on Anti-Cancer Drug Discovery
Title:Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review
Volume: 10 Issue: 3
Author(s): Douglas R. Abdalla, Cindy Simoens, John-Paul Bogers, Eddie F.C. Murta and Marcia A. Michelin
Affiliation:
Keywords: Angiogenesis, biomarkers, endoglin, gynecologic cancer, microvessel density, VEGF.
Abstract: The formation of a tumor-associated vascular network is an important step in understanding the stages of tumor progression. This review aims to highlight the main markers of induction, proliferation and inhibition of angiogenesis, as well as the quantification of microvessel density, correlated with preclinical and clinical research in gynecologic cancers and also discussed related patents. Studies show that in the most advanced cases of gynecological cancers, biomarkers such as VEGF (Vascular Endothelial Growth Factor), MMP (Matrix Metalloproteinase), CD105 (Endoglin), TIMP (tissue inhibitors of metalloproteinases) and VASH (Vasohibin) are more expressed compared to healthy individuals. Continuous evaluation of these biomarkers in cancer cases could serve in the future as a basis for development of new therapeutic approaches, leading to a good response to cancer treatment, and thus increase survival of cancer patients.
Export Options
About this article
Cite this article as:
Abdalla R. Douglas, Simoens Cindy, Bogers John-Paul, Murta F.C. Eddie and Michelin A. Marcia, Angiogenesis Markers in Gynecological Tumors and Patents for Anti- Angiogenic Approach: Review, Recent Patents on Anti-Cancer Drug Discovery 2015; 10 (3) . https://dx.doi.org/10.2174/1574892810999150827153642
DOI https://dx.doi.org/10.2174/1574892810999150827153642 |
Print ISSN 1574-8928 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3970 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Synthesis and Biological Evaluation of the Salicylamide and Salicylic Acid Derivatives as Anti-Estrogen Agents
Medicinal Chemistry Notch Signaling Proteins: Legitimate Targets for Cancer Therapy
Current Protein & Peptide Science Anti-Cancer/Anti-Tumor
Current Bioactive Compounds Changes in the Apoptotic and Survival Signaling in Cancer Cells and Their Potential Therapeutic Implications
Current Cancer Drug Targets Synthesis and Biological Evaluation of Novel Thiazol-2yl-amine Derivatives as Potential Anticancer Agents
Letters in Organic Chemistry Current Clinical Applications of In Vivo Magnetic Resonance Spectroscopy and Spectroscopic Imaging
Current Medical Imaging Berberine Exerts Anti-cancer Activity by Modulating Adenosine Monophosphate- Activated Protein Kinase (AMPK) and the Phosphatidylinositol 3-Kinase/ Protein Kinase B (PI3K/AKT) Signaling Pathways
Current Pharmaceutical Design A Review of Natural and Synthetic Antioxidants Important for Health and Longevity
Current Medicinal Chemistry Disintegrins from Snake Venoms and their Applications in Cancer Research and Therapy
Current Protein & Peptide Science LPA and its Analogs-Attractive Tools for Elucidation of LPA Biology and Drug Development
Current Medicinal Chemistry Transdermal Oxandrolone: Ex Vivo Percutaneous Absorption Study
Current Drug Delivery Namitecan: a Hydrophilic Camptothecin with a Promising Preclinical Profile
Current Medicinal Chemistry Optimization of the Enzymolysis Conditions for Scorpion Peptides and Evaluation of its Antitumor Activity
Current Signal Transduction Therapy Induction of GST and Related Events by Dietary Phytochemicals: Sources, Chemistry, and Possible Contribution to Chemoprevention
Current Topics in Medicinal Chemistry Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives
Current Molecular Pharmacology An Epigenetic Approach to Pancreatic Cancer Treatment: The Prospective Role of Histone Deacetylase Inhibitors
Current Cancer Drug Targets Synthesis of Silica Based Nanoparticles Against the Proliferation of Human Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Editorial: Drug Targets and Biomarkers for Obstetric/Gynecologic/Reproductive Diseases
Current Drug Targets Natural Products Containing Olefinic Bond: Important Substrates for Semi-synthetic Modification Towards Value Addition
Current Organic Chemistry